{"entity":{"id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","aka":[],"tldr":"Software, increasingly LLM-based, that reads a patient's record and finds trials or guideline options they qualify for.","summary":"AI trial matching software extracts structured data from the electronic health record, matches it against parsed eligibility criteria, and ranks trials or guideline options a patient may qualify for. The problem it targets is that only around 5-8% of adult cancer patients enter trials, partly because matching is manual. Tools include TrialGPT (NIH), Tempus TIME, Massive Bio, Deep 6 AI, and hospital-built LLM matchers, and molecular tumour boards use OncoKB and CIViC annotation for variant interpretation. The approach scales expert knowledge and could reduce disparities in trial access, but hallucination risk and the need for validation are live concerns, and eligibility criteria are often ambiguous even to humans. Evidence of increased enrolment is emerging but not yet definitive. The simple version is software that reads a patient's record and finds the trials they could join.","status":"established","asOf":"2026-09-04","links":[{"label":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes (JNCI: Journal of the National Cancer Institute 2019)","url":"https://doi.org/10.1093/jnci/djy221"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":["navexio","deep-6-ai","outcomes4me","triomics","yuga-bio","picnic-health","antidote","mytomorrows","klineo","galen","opencancerai","sagely-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["razelle-kurzrock"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Structured data are extracted from the EHR, matched against parsed eligibility criteria, and ranked.","strengths":["Scales expert knowledge","Reduces disparities in trial access"],"limitations":["Hallucination risk; validation","Eligibility criteria are ambiguous"]},"route":"/technologies/ai-trial-matching/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"}],"company":[{"id":"antidote","kind":"company","name":"Antidote","route":"/companies/antidote/"},{"id":"cancer-commons","kind":"company","name":"Cancer Commons","route":"/companies/cancer-commons/"},{"id":"deep-6-ai","kind":"company","name":"Deep 6 AI","route":"/companies/deep-6-ai/"},{"id":"galen","kind":"company","name":"Galen","route":"/companies/galen/"},{"id":"klineo","kind":"company","name":"Klineo","route":"/companies/klineo/"},{"id":"massive-bio","kind":"company","name":"Massive Bio","route":"/companies/massive-bio/"},{"id":"mytomorrows","kind":"company","name":"myTomorrows","route":"/companies/mytomorrows/"},{"id":"navexio","kind":"company","name":"Navexio","route":"/companies/navexio/"},{"id":"opencancerai","kind":"company","name":"OpenCancerAI","route":"/companies/opencancerai/"},{"id":"outcomes4me","kind":"company","name":"Outcomes4Me","route":"/companies/outcomes4me/"},{"id":"patient-data-vault","kind":"company","name":"Patient Data Vault (data-vault.health)","route":"/companies/patient-data-vault/"},{"id":"picnic-health","kind":"company","name":"Picnic Health","route":"/companies/picnic-health/"},{"id":"sagely-health","kind":"company","name":"Sagely Health","route":"/companies/sagely-health/"},{"id":"strata-oncology","kind":"company","name":"Strata Oncology","route":"/companies/strata-oncology/"},{"id":"tempus","kind":"company","name":"Tempus AI","route":"/companies/tempus/"},{"id":"trial-library","kind":"company","name":"Trial Library","route":"/companies/trial-library/"},{"id":"trinetx","kind":"company","name":"TriNetX","route":"/companies/trinetx/"},{"id":"triomics","kind":"company","name":"Triomics","route":"/companies/triomics/"},{"id":"yuga-bio","kind":"company","name":"Yuga Bio","route":"/companies/yuga-bio/"}],"person":[{"id":"eliezer-van-allen","kind":"person","name":"Eliezer M. Van Allen","route":"/people/eliezer-van-allen/"},{"id":"razelle-kurzrock","kind":"person","name":"Razelle Kurzrock","route":"/people/razelle-kurzrock/"}],"idea":[{"id":"idea-bio2-mrd-clinic-service","kind":"idea","name":"A dedicated clinic for people whose blood test says the cancer is back","route":"/ideas/idea-bio2-mrd-clinic-service/"},{"id":"idea-moon-global-open-trials-os","kind":"idea","name":"A global open trials operating system any hospital can plug into","route":"/ideas/idea-moon-global-open-trials-os/"},{"id":"idea-tr1-live-trial-slot-api","kind":"idea","name":"A live 'seats available' feed for trial slots, like airline inventory","route":"/ideas/idea-tr1-live-trial-slot-api/"},{"id":"idea-tr1-tumour-board-trial-line-item","kind":"idea","name":"A mandatory trial line in every tumour board recommendation","route":"/ideas/idea-tr1-tumour-board-trial-line-item/"},{"id":"idea-bio2-national-mrd-platform","kind":"idea","name":"A national platform trial that every ctDNA-positive patient can join","route":"/ideas/idea-bio2-national-mrd-platform/"},{"id":"idea-data-standard-of-care-api","kind":"idea","name":"A public API serving the current standard of care for any cancer, stage and biomarker","route":"/ideas/idea-data-standard-of-care-api/"},{"id":"idea-cost-travel-teleoncology","kind":"idea","name":"Bring the oncologist to the local clinic by video and the drug to the local pharmacy","route":"/ideas/idea-cost-travel-teleoncology/"},{"id":"idea-tr1-esource-ehr-to-edc","kind":"idea","name":"Direct record-to-database data capture: no manual transcription, no full source verification","route":"/ideas/idea-tr1-esource-ehr-to-edc/"},{"id":"idea-data-dynamic-consent-app","kind":"idea","name":"Dynamic consent with usage receipts","route":"/ideas/idea-data-dynamic-consent-app/"},{"id":"idea-tr1-ngs-report-live-trial-match","kind":"idea","name":"Every tumour sequencing report lists open, nearby, matched trials pulled live","route":"/ideas/idea-tr1-ngs-report-live-trial-match/"},{"id":"idea-tr1-just-in-time-site-network","kind":"idea","name":"Just-in-time site activation: open a site in two weeks when a patient appears","route":"/ideas/idea-tr1-just-in-time-site-network/"},{"id":"idea-bio2-rare-cancer-umbrella-platform","kind":"idea","name":"One standing umbrella trial for all rare cancers in a country","route":"/ideas/idea-bio2-rare-cancer-umbrella-platform/"},{"id":"idea-multimodal-foundation-model","kind":"idea","name":"Patient-level multimodal foundation models for treatment selection","route":"/ideas/idea-multimodal-foundation-model/"},{"id":"idea-moon-trial-eligibility-at-every-decision","kind":"idea","name":"Patients are told which trials they qualify for at every treatment decision, in writing","route":"/ideas/idea-moon-trial-eligibility-at-every-decision/"},{"id":"idea-tr1-eligibility-impact-statement","kind":"idea","name":"Simulate eligibility against real-world data before every protocol is locked","route":"/ideas/idea-tr1-eligibility-impact-statement/"},{"id":"idea-cost-trial-enrolment-cost-lever","kind":"idea","name":"Treat trial enrolment as a cost lever: the sponsor pays for the drug","route":"/ideas/idea-cost-trial-enrolment-cost-lever/"},{"id":"idea-tr1-ehr-point-of-care-trial-alert","kind":"idea","name":"Trial matching inside the electronic record at the moment a treatment is chosen","route":"/ideas/idea-tr1-ehr-point-of-care-trial-alert/"}],"collection":[{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/"}],"technology":[{"id":"variant-knowledgebases","kind":"technology","name":"Cancer variant knowledgebases and molecular tumour boards","route":"/technologies/variant-knowledgebases/"},{"id":"ngs-bioinformatics-software","kind":"technology","name":"Clinical NGS bioinformatics and variant interpretation","route":"/technologies/ngs-bioinformatics-software/"},{"id":"clinical-trial-software","kind":"technology","name":"Clinical trial software (EDC, eCOA, CTMS, RTSM)","route":"/technologies/clinical-trial-software/"},{"id":"community-oncology-networks","kind":"technology","name":"Community oncology and site networks","route":"/technologies/community-oncology-networks/"},{"id":"digital-twins-trials","kind":"technology","name":"Digital twins and virtual control arms","route":"/technologies/digital-twins-trials/"},{"id":"med-gemini","kind":"technology","name":"Med-Gemini and MedLM (Google)","route":"/technologies/med-gemini/"},{"id":"n-of-1-platforms","kind":"technology","name":"N-of-1 and rapid platform trials","route":"/technologies/n-of-1-platforms/"},{"id":"oncology-real-world-data","kind":"technology","name":"Oncology EHR and real-world data platforms","route":"/technologies/oncology-real-world-data/"},{"id":"telehealth-oncology","kind":"technology","name":"Telehealth and hospital-at-home in oncology","route":"/technologies/telehealth-oncology/"}],"bottleneck":[{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/"},{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/"},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/"},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/"},{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/"},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/"}],"paper":[{"id":"paper-unger-trial-participation-barriers-jnci-2019","kind":"paper","name":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes","route":"/key-papers/paper-unger-trial-participation-barriers-jnci-2019/"}],"term":[{"id":"accrual","kind":"term","name":"Accrual and enrolment","route":"/terms/accrual/"},{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"decentralised-trial","kind":"term","name":"Decentralised trial","route":"/terms/decentralised-trial/"},{"id":"master-protocol","kind":"term","name":"Master protocol (platform, basket and umbrella trials)","route":"/terms/master-protocol/"},{"id":"trial-registration","kind":"term","name":"Trial registration and results reporting (ClinicalTrials.gov, EU CTR)","route":"/terms/trial-registration/"}],"institution":[{"id":"hl7","kind":"institution","name":"HL7 International","route":"/institutions/hl7/"}],"roadmap":[{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/"},{"id":"ai-oncology-clinic","kind":"roadmap","name":"AI in the oncology clinic: from narrow cleared tools to multimodal decision support","route":"/roadmaps/ai-oncology-clinic/"},{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/"}],"trial":[{"id":"target-national","kind":"trial","name":"TARGET National","route":"/trials/target-national/"}]}}